The company had intended to raise up to €6.6 million through the placement to help fund its planned acquisition of TGR Biosciences.
Sygnis said that TGR is profitable and has a complementary product portfolio that includes protein capture technology.
Thermo Fisher said that IntegenX complements and enhances its existing human identification product portfolio.
Near-term the deal gives Quanterix a CLIA lab while securing technologies that could improve assay multiplexing and support its longer term clinical goals.
IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.
Advanced Analytical markets CE instruments, reagents, and software for nucleic acid analysis while Lasergen is a next-generation sequencing technology developer.
Through the deal, BioDuro has acquired Molecular Response's translational oncology research platform and its biobank of viable tumor specimens.
Genoptix's $9 million bid for Rosetta comes just days after the companies' first merger agreement failed to secure shareholder approval.
The company said PerkinElmer will pay A$.28 per share for its 89.9 million outstanding shares, a 100 percent premium to RHS's Feb. 23 closing price on the ASX.
Genoptix terminated the merger agreement after an insufficient number of Rosetta shareholders voted in favor of the deal.
Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.
Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.
Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.
In Nature this week: sequenced genomes of five additional Neanderthals, and more.